If considering starting a patient on the nucleoside reverse transcriptase inhibitor abacavir, the following testing is recommended prior to prescribing:

Question

Quizplus · Accepted Answer

Prior to prescribing abacavir, HLA B*5701 testing should be done to screen for potential hypersensitivity reactions. Renal function should also be monitored during treatment, but it is not required prior to starting therapy. Pancreatic enzyme levels and CYP 450 enzyme activity are not relevant to abacavir use.

If Considering Starting a Patient on the Nucleoside Reverse Transcriptase